市場調查報告書
商品編碼
922053
全球血漿蛋白質治療藥市場:成長,趨勢,及預測Plasma Protein Therapeutics Market - Growth, Trends, and Forecast (2022 - 2027) |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
本報告提供全球血漿蛋白質治療藥市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,產品·用途·各地區的市場分析,競爭情形,主要企業的簡介等資訊。
The plasma protein therapeutics market studied has been projected to register a CAGR of nearly 5.3% over the forecast period 2021-2026.
The COVID-19 pandemic is expected to have a significant impact on the global market. In the context of the COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms are focusing on effective and rapid technologies for the fast diagnosis of COVID-19 and developing vaccines and new therapeutics to overcome the current situation. The COVID-19 is also affecting the global economy by directly affecting production and demand and creating supply chain and market disruption, with financial impact on the firms and financial markets. The current COVID-19 pandemic has also temporarily impacted plasma donation globally, affecting the plasma protein therapeutics market. However, researchers are focusing on plasma-based therapeutics to identify whether these therapies have any promising role in treating the COVID-19 virus. For instance, in April 2020, Kamada Ltd. and Kedrion Biopharma, two biopharmaceutical companies specialized in plasma-derived protein therapeutics, entered a global collaboration for the development, manufacturing, and distribution of a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for COVID-19 patients.
In April 2020, the Indian Council of Medical Research (ICMR) pursued the participation of researchers for conducting a clinical trial of convalescent plasma therapy to treat critically ill COVID-19 patients and floated a protocol for it. In May 2020, BioAegis Therapeutics started researching its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), believing it as a viable therapeutic option for patients suffering from severe lung injury due to COVID-19.
The major factors that are leading to the growth of the market include the increasing prevalence of autoimmune disorders, immune deficiency disorders, neurological and bleeding disorders. Along with these factors, the rise in the geriatric population across the globe is a major reason for market growth as elderly people are more prone to neurological disorders.
Furthermore, the growing investments in research and development programs by biotechnology and pharmaceutical companies are boosting the market growth. The current happening research and development in the plasma protein segment are anticipated to drive its use through several applications. The increase in the usage of therapeutic protein drugs in the treatment of a wide range of clinical symptoms is projected to generate unique growth opportunities for this market in the coming years.
However, the stringent regulations for the handling of plasma protein products and the lack of proper reimbursement policies are the major drawbacks that are hindering the market growth.
Hemophilia is a unique bleeding disorder of genetic origin that prevents the normal clotting of blood. The major symptom of this disorder is uncontrolled and often causes spontaneous bleeding in different areas of the body. The amount of bleeding depends on the severity of hemophilia. According to the World Federation of Hemophilia report 2019, the number of people identified with Hemophilia increased from 78,629 in 1999 to 210,454 in 2018. Additionally, as per the Global Hemophilia Care 2019 report, more than 1,125,000 men worldwide have an inherited bleeding disorder, and 418,000 of those have a severe version of the most undiagnosed disease. Hemophilia A is the most prevalent type of the condition, with an incidence rate of 1 in 4,000 to 1 in 5,000 males worldwide born with this disorder. Hemophilia B occurs in approximately 1 in 20,000 newborn males across the world. The increasing prevalence of hemophilia and the huge patient pool are expected to trigger market growth during the forecast period. Moreover, the increasing R&D research on the development of new therapeutics and product launches are expected to boost the segment growth over the forecast period. For instance, in October 2018, the United States Food and Drug Administration (FDA) approved Roche's Hemlibra for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, newborns, and the elderly, with hemophilia A without factor VIII inhibitors. The increasing geriatric population is also expected to boost demand for plasma protein therapeutics.
North America is expected to dominate the overall plasma protein therapeutics market throughout the forecast period. The market growth is due to factors like the increasing prevalence and incidence of autoimmune and neurological diseases. The United States is expected to be the largest market in this region.
The well-established healthcare infrastructure-focused market players on R&D for plasma protein therapeutics, coupled with recent product launches and the rising burden of autoimmune disorders, are primary growth factors for the market in the United States. According to the Centers for Disease Control and Prevention (CDC), in 2018, about 70% of people with hemophilia in the United States receive multidisciplinary, comprehensive care in a network of federally funded hemophilia treatment centers. According to the United States Arthritis Foundation, arthritis is the leading cause of disability among adults. By conservative estimates, about 54 million adults were diagnosed with arthritis, and almost 300,000 children are suffering from arthritis or rheumatic condition (as of 2017-2018). According to a study published by Derek Weycker, in October 2019, the annual incidence of immune thrombocytopenia (ITP) in the United States was 6.1 per 100,000 persons, higher among females versus males (6.7 vs. 5.5), and highest among children aged between 0 and 4 years (8.1) and adults aged 65 years and above (13.7). Furthermore, there has been an increased focus on convalescent plasma therapy to treat COVID-19 in the United States. In April 2020, Johns Hopkins got the FDA approval to test blood plasma therapy to treat COVID-19 patients. The United States Food and Drug Administration issued guidance to provide recommendations for investigational convalescent plasma therapy. Thus, the market for plasma protein therapeutics is projected to experience significant growth in the United States.
The increasing geriatric population in this region also increases the patient pool, like the elderly are more prone to neurological diseases. Furthermore, beneficial government initiatives, escalating awareness levels among the blood donors, the existence of advanced protein fractioning procedures, greater per capita income in developed countries, and an increase in the number of research partnerships are some of the drivers expected to increase market growth the region.
The plasma protein therapeutics market is moderately competitive and consists of several major players. Some companies currently dominating the market are Takeda Pharmaceutical Company Ltd, Octapharma USA Inc., Grifols, SA, CSL Behring, Biotest AG, Baxter, China Biologic Products Holdings Inc. al Company Ltd, Octapharma USA Inc., Grifols SA, and CSL Behring.